Loading clinical trials...

Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury | Clinical Trials | Clareo Health

RECRUITINGPHASE1/PHASE2

Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

NCT06836856•Mansoura University

View on ClinicalTrials.gov

Summary

Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1\. Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries.
•Minor injuries are defined as presence of any of the following:
•1. Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound.
•2. mild lung contusion detected in the chest CT scan.
•3. hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress.
•4. simple limb fractures.

Exclusion Criteria

•1. Patients on pre-injury beta-blocker therapy.
•2. Patients with any bronchospastic conditions.
•3. Patients with active acute coronary syndrome.
•4. TBI with GCS ≤ 13 with associated major injuries defined as the presence of any of the following:
•1. Moderate \& marked IPFF requiring surgical intervention ( laparotomy ).
•2. moderate \& marked lung contusion, pneumothorax \& hemothorax with accompanying symptoms of hypoxia, tachypnea, lower limbs, or limb amputation.
•3. Compound fracture in the upper or lower limb.
•4. Open Faciomaxillary trauma.
•5. Patients with persistent shock (systemic blood pressure \<100 mmHg, base deficit \> 4, or oliguria , HR \< 60 b/min ) after \> one week of admission.

Locations (2)

Zagazig University Hospitals, Zagazig,

Zagazig, Egypt

Zagazig University Hospitals

Zagazig, Egypt

Key Dates

Start Date

January 20, 2025

Primary Completion Date

June 1, 2025

Completion Date

June 1, 2025

Last Updated

April 2, 2025

Enrollment

100

ESTIMATED participants

Conditions

TBI Traumatic Brain Injury

Interventions

control

DRUG

propranolol

DRUG

Carvedilol

DRUG

Contacts

Aya Osama Nagaty

CONTACT

00201097721011 doctoraya_15@yahoo.com

Efficacy of Early Continuous Infusion of HSS on the Neurological Outcome at 6 Months in TBI Patients.

NCT07319208

TBI Traumatic Brain Injury

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions